|
Have you recently changed roles or institutions? Applied for new funding? If you have news to share, please update this Contact Form or send an email to Emily Kay. We look forward to hearing from you!
|
|
|
|
|
Upcoming CURE Funding Deadlines
Research Supplements to Promote Diversity in Health-Related Research (DS) | PA-20-166 | Applications are due Oct. 1 - Dec. 31, 2020 and Feb. 1 - April 30, 2021
Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers | PA-18-592 | Applications are due Oct. 1 - Dec. 31, 2020 and Feb. 1 - April 30, 2021
Please use these updated Diversity Supplements Guidelines and Re-Entry Supplements Guidelines along with DS fact sheet to prepare your application.
Kirschstein-NRSA Individual Predoctoral Fellowship to Promote Diversity in Health Related Research (F31-Diversity) | PA-19-196 | Applications are due Aug. 8, 2020, Dec. 8, 2020, and April 8, 2021
NCI Mentored Research Scientist Development Award to Promote Diversity (K01) | PAR-18-364 | PAR-18-365 | Applications are due June 12, 2020, Oct. 12, 2020 and Feb 12, 2021.
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08) | PAR-18-337 | PAR-18-336 | Applications are due June 12, 2020, Oct. 12, 2020 and Feb 12, 2021.
NCI Transition Career Development Award to Promote Diversity (K22) | PAR-18-366 | PAR-18-367 | Applications are due June 12 and Oct. 12, 2020
NCI Youth Enjoy Science Research Education Program (R25) | PAR-17-059 | Applications are due May 25, 2020, Sept. 25, 2020 and Jan 25, 2021.
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) | PAR-18-731 | Application are due June 19 and Nov. 19, 2020.
Basic Research in Cancer Health Disparities (R21/R01) | PAR-18-654 | PAR-18-655 | Application are due June 19 and Nov. 19, 2020.
Upcoming Non-CURE Funding Opportunities
New! Administrative Supplements for Development of Risk-Stratified Cancer Survivorship Care Algorithms | NOT-CA-20-038 | Submissions must be received by May 15, 2020.
Risk-stratified cancer survivorship care tailors follow-up care based on the level of need of the survivor (e.g., risk for recurrence, subsequent malignancies, physical and/or psychosocial sequelae). This Notice of Special Interest informs current National Cancer Institute (NCI) grant awardees that the NCI is seeking supplement applications that develop and/or validate algorithms that categorize survivors into meaningful risk-stratified groups in order to inform appropriate follow-up care.
Upcoming deadline! Notice of Special Interest: Availability of Administrative Supplements for Research in Geographically Underserved Areas | NOT-CA-20-035 | Applications are due May 15, 2020 at 5 p.m. local time.
This notice informs the current NCI R01 awardees of NCI’s special interest in administrative supplement applications that seek to address cancer control research in “geographically underserved areas.” For the purposes of this notice, geographically underserved areas refers to (1) areas and populations with high and/or persistent poverty, or (2) areas and populations living with high and/or persistent poverty in Health Professional Shortage Areas (HPSAs) or Frontier and Remote (FAR) area zip codes (definition and FAR codes can be found at: https://www.ers.usda.gov/data-products/frontier-and-remote-area-codes). For more information, please click here to see the full notice.
New! Notice of Special Interest: Administrative Supplement Opportunity to Stimulate or Strengthen Global Cancer Health Disparities Research | NOT-CA-20-032 | Due date: May 15, 2020
Extended deadline! Research Answers to National Cancer Institute's (NCI) Provocative Questions (R01/R21 Clinical Trial Optional) | Applications due June 2, 2020 | RFA-CA-20-004 | RFA-CA-20-005
The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to this FOA must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ.
FOA for Building Population Health Research Capacity in the U.S. Affiliated Pacific Islands
Very little information regarding the specific health status of U.S.-Affiliated Pacific Islands (USAPI) populations is available. There is a critical need to collect basic epidemiological and health services data for USAPI populations residing in the region. NIMHD is supporting a new funding opportunity to build local organizations’ capacity to conduct ongoing population health research in the USAPI. The funding will support population health research projects that will provide novel data for USAPI populations and serve as the foundation for future research efforts. Click here to learn more.
Open Date (Earliest Submission Date): June 15, 2020
Application Due Date: July 15, 2020, by 5:00 p.m. local time of applicant organization
Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) | PAR-18-655 | Applications are due June 19 and Nov. 19, 2020.
Administrative Supplements to Support Cancer Disparity Collaborative Research | Due dates: September 10, 2020
Description: If you hold an active NCI-funded R01 (with at least 2 years of support remaining) and are interested in expanding your research to incorporate a cancer disparities research project, please consider submitting a proposal under FOA PA-18-842: Administrative Supplements to Support Cancer Disparity Collaborative Research. Please note that for this FOA, collaborative teams are required between a non-cancer disparities investigator (PI of the R01) and a collaborator who has minority health research or cancer disparities research expertise.
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | PAR-18-869 | Application due date November 6, 2020; March 8, 2021
Expiration Date: September 11, 2020
The Sexual & Gender Minority Research Office (SGMRO) is pleased to announce the publication of a Notice of Special Interest (NOSI) regarding Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (NOT-OD-20-032).
Purpose: This Notice of Special Interest (NOSI) announces the availability of administrative supplements to provide funding for the expansion of existing research projects to incorporate sexual and gender minority (SGM) populations, which include, but are not limited to, those populations described in Notice NOT-OD-19-139. Basic, social, behavioral, clinical, translational, and health services research relevant to the missions of the sponsoring NIH Institutes or Centers (ICs) may be proposed in response to this solicitation. Potential applicants are also encouraged to review the FY 2017 Portfolio Analysis of NIH-funded SGM research to identify potential research gaps that may be relevant to this NOSI.
Application Due Dates January 25, 2021 for FY 2021, by 5:00 PM local time of applicant organization.
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01/R21 Clinical Trial Optional) | PA-18-738 | PA-18-739 | Application Due: Standard dates apply.
Expiration Date: May 8, 2021
Administrative Supplements to Promote Diversity in Research and Development Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed) | PA-18-837 | Expiration date: Sept. 5, 2021
NCI SBIR Administrative Supplements for Activities to Accelerate the Development and Commercialization of Cancer-Related Innovations | NOT-CA-20-012 | Expiration date: March 18, 2022
Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01/R21 Clinical Trials Not Allowed) | PAR-20-088 | PAR-20-081 | Expiration date: April 02, 2022
NCI's Healthcare Delivery Research Program (HDRP) Funding Opportunities
Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20, Clinical Trials Optional) | Application are due June 19, 2020, and October 18, 2020 | RFA-CA-19-034
Purpose: The goals for this FOA include developing translational research programs focused on investigating cancer disparities. The P20 grants will support feasibility and planning activities to build cancer disparities research programs, with the expectation that the research programs will become competitive for a full P50 SPORE. Reissue of RFA-CA-17-034 (resubmissions will be accepted). New restrictions: Due to a focus on understudied areas of cancer disparities, applications proposing prostate and breast cancer projects are not responsive for this issuance.
Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional) | PA-17-495 | Standard dates apply. Expiration date January 8, 2021.
Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R21/R01 Clinical Trial Not Allowed) | Applications are due March 4, 2021 | PAR-19-019 | PAR-19-018
Purpose: The purpose of this initiative is to promote multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.
Co-infection and Cancer (R01/R21 Clinical Trial Not Allowed) | PAR-20-062 | PAR-20-061 | Standard dates apply
The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection.
New Funding Opportunities
New! Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19) | NOT-CA-20-042 | Expiration Date: June 26, 2020
New! Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19) | NOT-CA-20-043 | Expiration Date: June 26, 2020
Notice of Special Interest (NOSI): NCI's Research Interests to Improve Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment | NOT-CA-19-059
Contact: Sallie Weaver Application Due Date: This NOSI applies to due dates on or after September 25, 2019 through January 8, 2022. Applications related to this NOSI may be submitted using the following funding opportunity announcements or future reissuances: PAR-18-869, PAR-18-559, PA-19-056, PAR-18-290 An informational webinar is being planned. Please check our website for updates.
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization | PAR-19-352 (R01), PAR-19-355 (R21) | Expiration Date: September 8, 2022
Contact: Michelle Mollica
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake | PAR-19-360 (R01), PAR-19-358 (R21), PAR-19-359 (R03) | Expiration Date: September 8, 2022 (R01 and R21); July 17, 2022 (R03)
Contact: Sarah Kobrin
Dissemination and Implementation Research in Health | PAR-19-274 (R01), PAR-19-275 (R21), PAR-19-276 (R03) | Expiration Date: May 8, 2022
Contact: Gila Neta, Wynne E. Norton, and David Chambers (from the DCCPS Implementation Science Team)
Funding Opportunity Announcement for Dissemination and Implementation Research in Health (R01/R21/R03) The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, developing, testing, evaluating and/or refining strategies to disseminate and implement evidence-based practices
Funding Opportunity Announcement Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01/R03/R21) This FOA encourages research on how the health care delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and health care delivery.
Application Due Dates:
Other Funding Opportunities
New! Notice of Special Interest: Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities | NOT-MD-20-019 | Earliest Submission Date: May 1, 2020 | Expiration date: May 1, 2021
NIMHD is issuing a Notice of Special Interest (NOSI) soliciting research in health disparity populations that -seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations.
New! NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) | PAR-20-150 | Earliest Submission Date: May 16, 2020 | Expiration date: May 8, 2023
NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.
New NIH "FORMS-F" Grant Application Forms and Instructions Coming for Due Dates on or after May 25, 2020
This notice states that the following application forms include substantive changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change. NOT-OD-20-026
- PHS 398 Career Development Award Supplemental Form
- PHS 398 Cover Page Supplement
- PHS Assignment Request form
- PHS Fellowship Supplemental Form
- PHS Human Subjects and Clinical Trials Information
- SBIR/STTR Information
CMS Minority Research Grant Program | June 2, 2020 | CMS-1W1-20-001
The Office of Minority Health at the Centers for Medicare and Medicaid Services (CMS) will make two awards of $250,000 each to support research at minority-serving institutions. Eligible applicants are public and private institutions of higher education that can enhance CMS capacity for reducing health disparities in minority populations.
Notice of Intent to Publish a Funding Opportunity Announcement for Strengthening Institutional Capacity to Conduct Global Cancer Research (D43) | Application Due Date: June 30, 2020
The NCI intends to publish a FOA inviting applications from U.S.-based cancer-research intensive institutions who propose research training programs working in collaboration with a low-and middle-income country (LMIC) institution to strengthen capacity to conduct global research. NOT-CA-20-015
New! Mechanisms and Consequences of Sleep Disparities in the U.S. (R01 - Clinical Trial Not Allowed) | PAR-20-164 | Application Due Dates: July 14, 2020, July 14, 2021, July 14, 2022
Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R01 Clinical Trial Optional) | PAR-18-493 | PAR-18-492 | Expiration date: May 8, 2021
Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional) | PA-18-932 | Expiration date: January 08, 2022
Additional Resources
Standard Application Deadlines: For more on standard applications deadlines visit: https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/due-dates.htm Program staff are available to answer questions. Contact information and funding resources are available online.
Sample Grant Applications: The National Cancer Institute (NCI) frequently receives questions from investigators for examples of successfully funded grant applications. Several investigators and their organizations agreed to let the Division of Cancer Control & Population Sciences (DCCPS) programs post excerpts of their grant applications online.
|
|
|
Challenge: Design by Biomedical Undergraduate Teams (DEBUT) | Deadline is June 1.
The NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) and Venture Well are challenging undergraduate student teams to develop technology solutions to unmet needs in the areas of technologies for underrepresented populations and/or for low-resource settings, and technologies for HIV/AIDS prevention and/or care. To learn more please click here.
SciTS 2020 | The International Science of Team Science Conference Durham, North Carolina, USA | June 1-4, 2020
As the leading international conference for the Science of Team Science, SciTS 2020 will focus on highlighting and pursuing excellence in studying, doing, and teaching team science. The event has gone virtual! Learn more and keep up-to-date here.
|
|
American Indian College Fund: Full Circle Scholarship. Provides financial assistance to AI/AN students seeking undergraduate and graduate degrees at Tribal colleges/universities or nonprofit schools. Application period ends May 31, 2020. Learn more.
|
|
The American Association for Cancer Research (AACR) is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Committed to building and training a diverse cancer research workforce, the AACR invests in the training of the next generation of cancer researchers and early-career investigators by offering the following Educational Workshops in 2020.
Due to the evolving response to COVID-19, please monitor the websites below for any changes to upcoming workshops.
Integrative Molecular Epidemiology Workshop: Bridging Cancer Biology and Precision Medicine (Boston, MA)
Molecular epidemiologists, geneticists, statisticians, bioinformaticians, molecular biologists, physician-scientists, and others who have completed basic coursework in epidemiology will be trained in the integration of biology and epidemiology in studies of cancer etiology and disease outcome.
Application deadline: Monday, April 13, 2020
For more information: www.aacr.org/ime20 | Contact: Shakira Nelson (shakira.nelson@aacr.org)
Translational Cancer Research for Basic Scientists Workshop (Boston, MA)
Basic scientists at the pre- or postdoctoral level and early-career scientists will gain an in-depth understanding of translational research, enabling the adaptation of their research for maximum clinical impact and transition into translational cancer medicine.
Application deadline: Thursday, May 7, 2020
For more information: www.aacr.org/tcr20 | Contact: Lyngine Calizo (lyngine.calizo@aacr.org)
|
|
|
NCATS is looking for innovative partners to join its dynamic team. Learn more about current job opportunities at NCATS or across NIH and the U.S. Department of Health and Human Services (HHS).
All information provided by candidates will remain confidential and will not be released outside the NCATS search process without a signed release from candidates. The NIH encourages the application and nomination of qualified women, minorities and individuals with disabilities. DHHS and NIH are Equal Opportunity Employers. NIH is dedicated to building a diverse community in its training and employment programs.
Current Vacancies:
Postdoctoral Positions in the Division of Pre-Clinical Innovation
More Career Opportunities & Resources
|
|
|
Resources & Tools
Guidance and Resources for Applicants
- Coronavirus 2019 (COVID-19) Information for Applicants and Recipients
- Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19 - NOT-OD-20-086
- General Frequently Asked Questions (FAQs) - Proposal Submission and Award Management Related to COVID-19 - NOT-OD-20-083
- NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19) - NOT-OD-20-091
Visit the GMaP Group for additional tools and resources for researchers, such as links to biospecimens, biorepositories, and statistician tools!
News
Taking the ‘FIRST’ Step to Diversify the Professoriate: Systematic Approach
NIH recently took a major step in addressing the gap in underrepresented biomedical research faculty—a pioneering program (lead in part by our office) is attempting to create scientific cultures of inclusion, by integrating cohorts of faculty from diverse backgrounds into the professoriate. This initiative, the Faculty Institutional Recruitment for Sustainable Transformation (FIRST), will work to support over a dozen universities/medical schools, adding roughly 10 assistant professors at each institution. The proposed $241 million program would span 9 years and provide partial funds for: cohort hiring, start-up funds, professional development and mentoring, institution wide systems to address systemic/cultural issues, and a data coordination center to conduct independent program evaluation. Based on the cohort model literature and our similar, successful intramural initiative, the Distinguished Scholars Program, FIRST will recruit individuals with outstanding research qualifications who have demonstrated commitment to diversity and inclusion. You can find more information listed in the Science article here.
The National Institutes of Health and the Foundation for the NIH (FNIH) are bringing together more than a dozen leading biopharmaceutical companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration and the European Medicines Agency to develop an international strategy for a coordinated research response to the COVID-19 pandemic. The planned Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership will develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics.
NCI initiative aims to boost CAR T-cell therapy clinical trials
Researchers at the Center for Cancer Research are part of a new NCI initiative to manufacture CAR T-cell therapies for clinical trials being conducted at multiple hospitals. Nirali N. Shah, M.D., Lasker Clinical Research Scholar in the Pediatric Oncology Branch, is a co-lead investigator on the first trial of this initiative that is testing a CAR T-cell therapy designed to target a protein on cancer cells called CD33 in children and young adults with advanced forms of acute myeloid leukemia.
FDA approves first therapy for children with neurofibromatosis type 1
The Food and Drug Administration (FDA) has approved selumetinib (Koselugo) to treat children with neurofibromatosis type 1 (NF1) and tumors called plexiform neurofibromas. The approval was based on results from a clinical trial, designed and led by Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch (POB), and Andrea M. Gross, M.D., Assistant Research Physician in POB, that showed the drug shrank neurofibromas in 70 percent of patients. For many children in the trial, treatment with selumetinib also had clinical benefit, improving their pain, function and quality of life.
Additional news and a list of newsletters are available on our news page.
|
|
Screen to Save
This CRCHD initiative aims to increase colorectal screening rates among racial and ethnic minority communities nationwide. Working through the NCI-supported National Outreach Network, community health educators (CHEs) will provide culturally tailored, evidence-based colorectal cancer information, education, and screening resources within underserved populations.
Visit Screen to Save to learn more about this initiative.
|
|
|
Additional news and a list of newsletters are available on our news page.
|
|
|
|
